novo nordisk

Affordable generic versions of Ozempic and Wegovy have quickly secured 20% of the Rs 1,600 crore weight-loss market following patent expiry. Early movers like Torrent and Sun Pharma are challenging Eli Lilly's Mounjaro, with generics and lower pricing boosting semaglutide's market position.

Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following novo nordisk's patent expiry. This move significantly reduces therapy costs, offering patients greater access to treatment for obesity and type-2 diabetes. Torrent Pharma even introduced both oral and injectable versions, marking a significant step in addressing India's growing metabolic disorder crisis.

As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships

Zydus saw success with an oral GLP-1 drug in 2010, but shelved the drug's clinical development due to costs

Even five months after the announcement by health minister Laxmikant Parsekar in the assembly that government will review its agreement with novo nordisk, Goa medical college (GMC) continues to purchase insulin injections from the same company.

BANGALORE: novo nordisk Pharma India, the Indian subsidiary of Danish pharma major novo nordisk, has refuted allegations that the clinical trials of ragaglitazar, an insulin sensitiser used for the treatment of Type II diabetes, were conducted in an unethical manner.

Pfizer has agreed to acquire Metsera for $10 billion, outbidding novo nordisk in a heated competition. Metsera's board unanimously approved Pfizer's improved offer, citing significant legal and regulatory risks associated with the novo nordisk proposal. This acquisition highlights the intense race among pharmaceutical giants for a share of the booming global obesity and diabetes treatment market.

HYDERABAD: novo nordisk, a global drug major, has decided to dump the insulin sensitiser compound Ragaglitazar developed by the city-based Dr Reddy’s Laboratories. With this decision, all the activities to develop the compound will come to a halt.

HCL Technologies (HCL) has won a contract from Danish pharma major novo nordisk to provide global service desk and on-site support. HCL will help novo nordisk transform its IT operations and create world-class end-user experiences and drive efficiency across its workforce.

novo nordisk, maker of Ozempic and Wegovy, lowered its 2025 sales outlook for the fourth time, citing slower growth in diabetes and obesity treatments. The company announced 9,000 job cuts and is in a bidding war with Pfizer for Metsera, raising its offer to $10 billion.

NEW DELHI: Dr Reddy’s Laboratories on Monday said that cancellation of agreement between Novartis Pharma and novo nordisk to commercialise dual-acting insulin sensitiser for the treatment of Type 2 diabetes, would not affect the development of the drug.

HYDERABAD: novo nordisk has decided to dump the insulin sensitiser compound Ragaglitazar developed by the city-based pharma major Dr Reddy's Laboratories (DRL). With this decision, all the activities that are in the pipeline to develop the compound will come to a halt.

NEW DELHI: novo nordisk is in talks with a few global pharmaceutical majors to strike a commercial marketing agreement for a co-licenced anti-diabetes molecule under development, after a similar deal with Novartis fell through.

BANGALORE: Danish pharmaceutical company novo nordisk has been in the forefront of pharmaceutical, especially diabetes research for decades.

BANGALORE: Danish pharmaceutical company novo nordisk has been in the forefront of pharmaceutical, especially diabetes research for decades.

novo nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded versions of Ozempic and Wegovy, along with Eli Lilly's Zepbound gaining market share, contributed to the decision.